BioNTech Agrees to Buy Scholar Rock’s FDA Voucher for $205 Million

BioNTech announced Tuesday, Nov. 10, that it had agreed to pay $205 million for Scholar Rock’s U.S. Food and Drug Administration (FDA) priority review voucher, which it plans to use to speed review of a future oncology filing.

The planned application would involve an asset in BioNTech’s late-stage oncology pipeline. A priority review voucher gives one application priority review, shortening the FDA’s target review timeline.

The agreement is subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act. Payment is due upon closing.

The $205 million price is $2 million higher than the $203 million price in Ultragenyx’s voucher sale.